HSBC Holdings
IOVA icon

HSBC Holdings’s Iovance Biotherapeutics IOVA Stock Holding History

HSBC Holdings’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98K Sell
27,484
-153,057
-85% -$490K ﹤0.01% 2753
2025
Q4 		$497K Buy
180,541
+156,517
+652% +$362K ﹤0.01% 2318
2025
Q3 		$52.3K Sell
24,024
-18,673
-44% -$44.1K ﹤0.01% 2644
2025
Q2 		$73.7K Buy
42,697
+26,463
+163% +$65.8K ﹤0.01% 2893
2025
Q1 		$53.2K Sell
16,234
-15,711
-49% -$81K ﹤0.01% 2896
2024
Q4 		$232K Buy
31,945
+14,045
+78% +$130K ﹤0.01% 2635
2024
Q3 		$172K Buy
+17,900
New +$170K ﹤0.01% 2673
2024
Q2 		– Sell
-24,644
Closed -$365K – 3056
2024
Q1 		$365K Buy
+24,644
New +$287K ﹤0.01% 2290
2022
Q3 		– Sell
-10,744
Closed -$118K – 3092
2022
Q2 		$118K Buy
+10,744
New +$141K ﹤0.01% 3011
2021
Q4 		– Sell
-9,345
Closed -$231K – 3300
2021
Q3 		$231K Sell
9,345
-2,138
-19% -$50.4K ﹤0.01% 2699
2021
Q2 		$303K Buy
+11,483
New +$298K ﹤0.01% 2507
2021
Q1 		– Sell
-5,777
Closed -$271K – 2928
2020
Q4 		$271K Sell
5,777
-6,288
-52% -$250K ﹤0.01% 2634
2020
Q3 		$400K Buy
12,065
+3,372
+39% +$103K ﹤0.01% 2074
2020
Q2 		$239K Buy
+8,693
New +$286K ﹤0.01% 2245

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

HSBC Holdings's IOVA Position: Q1 2026 in Review

HSBC Holdings reduced its Iovance Biotherapeutics (IOVA) stake by 85% in Q1 2026, selling an estimated $490K and leaving 27,484 shares worth $98K. The position accounts for ﹤0.01% of the portfolio, ranked #2753.

HSBC Holdings first reported a position in IOVA in Q2 2020 and has held it in 14 quarters since. The position peaked at $497K in Q4 2025. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • HSBC Holdings held 27,484 shares of Iovance Biotherapeutics worth $98K as of Q1 2026.
  • HSBC Holdings sold 153,057 Iovance Biotherapeutics shares in Q1 2026, an estimated $490K.
  • Iovance Biotherapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2753 holding.
  • HSBC Holdings first reported a position in Iovance Biotherapeutics in Q2 2020 and has held it in 14 quarters since.
  • HSBC Holdings's Iovance Biotherapeutics position peaked at $497K in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.